A amplificação do oncogene N-myc no neuroblastoma: implicações prognósticas e o desenvolvimento de terapias-alvo
DOI:
https://doi.org/10.51473/rcmos.v1i1.2026.2408Keywords:
Neuroblastoma. Proteína Proto-Oncogênica N-Myc. Prognóstico. Terapia Molecular Alvo. Imunoterapia.Abstract
O neuroblastoma é a neoplasia sólida extracraniana mais comum na infância, caracterizada por elevada heterogeneidade clínica. Este estudo teve como objetivo investigar a correlação entre a amplificação do oncogene MYCN, o estadiamento e o prognóstico da doença, além de revisar terapias emergentes. Realizou-se uma revisão integrativa da literatura nas bases de dados PubMed, SciELO e Google Acadêmico, com seleção de 10 artigos publicados entre 2018 e 2026. Os resultados indicam que a superexpressão do MYCN é o principal preditor de mau prognóstico e de resistência, o que direciona o paciente ao protocolo de alto risco. Estratégias como terapias-alvo (via PI3K/Akt/mTOR) e imunoterapias (anti-GD2 e CAR-T) surgem como caminhos para contornar essa agressividade. Conclui-se que a oncologia de precisão é indispensável ao manejo da doença, evidenciando o papel estratégico do biomédico no diagnóstico molecular e na pesquisa translacional.
Downloads
References
PARK, J. R. et al. Anti-GD2 Immunotherapy for Neuroblastoma: Current State and Future Directions. Journal of Clinical Oncology, v. 36, n. 15, p. 1011-1020, 2018.
COCHRAN, M. et al. Neuroblastoma: from molecular pathogenesis to therapy. International Journal of Molecular Sciences, v. 21, n. 21, p. 7832, 2020.
SHARMA, S. et al. The role of the MYCN oncogene and its therapeutic implications in neuroblastoma. Molecular Cancer, v. 20, n. 1, p. 1–15, 2021.
ZAFAR, A. et al. Molecular mechanisms of MYCN-driven oncogenesis in neuroblastoma. Communications Biology, v. 4, n. 1, p. 1–12, 2021.
KAPPEL, S. et al. The Landscape of Targeted Therapies in Neuroblastoma. Cancers, v. 14, n. 3, p. 521, 2022.
VAN NIMWEGEN, L. et al. Prognostic relevance of MYCN amplification in neuroblastoma: an analysis of the SIOPEN database. European Journal of Cancer, v. 165, p. 142–152, 2022.
KAPPEL, S. et al. Targeting MYCN signaling in neuroblastoma. Nature Reviews Cancer, v. 23, p. 550–568, 2023.
SHARMA, S. et al. Targeting the PI3K/Akt/mTOR pathway in neuroblastoma. Frontiers in Cell and Developmental Biology, v. 11, p. 1051676, 2023.
CAFFERKEY, A. et al. CAR T-cell therapy for neuroblastoma: current status and future directions. Frontiers in Oncology, v. 13, n. 1, p. 1072170, 2024.
MEDSCAPE. New insights into the biology and treatment of high-risk neuroblastoma. Medscape Oncology Updates, 2025.
Published
Issue
Section
Categories
License
Copyright (c) 2026 Isabela Lopes Faria Barbosa, Ligia Canongia de Abreu Cardoso Duarte (Autor)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
